A partnership of highly experienced medicinal and computational chemists working at the cutting edge of modern drug design
We have more than 80 years of collective experience within drug discovery
We work with large pharma, small biotech, VC investors, academics and not-for-profit organisations to deliver novel hits, leads and preclinical candidate molecules and identify opportunities for in-licensing and out-licensing
Founded in 2011 by Drs Karl Gibson, James Mills and Gavin Whitlock, Sandexis Medicinal Chemistry has developed a global client base covering all aspects of small-molecule drug discovery. We specialise in delivering highly tailored solutions for our partners, including bespoke computational chemistry tools, project and target due diligence reviews and leadership of multi-partner virtual drug discovery projects.
What Makes Us Unique
Our experienced team has a proven track record for delivery at all stages of small-molecule drug discovery across multiple disease areas, target classes and delivery modalities. Our team-based approach, in close partnership with our clients, maximises the chances of a successful project outcome.